GlassScriptPhysician profile
Carlos Manuel Manalich
NPI 1003871997
$3,582.62
in general payments reported to CMS, 2019-2025
34 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $426 · 2021: $251 · 2022: $62.24 · 2023: $844 · 2024: $933 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.45 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $582.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $468.17 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $267.39 | 2019-2024 | Airsupra, Breztri |
| Lilly USA, LLC | $223.98 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Janssen Pharmaceuticals, INC | $197.74 | 2020-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $179.76 | 2023-2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $175.58 | 2019-2021 | |
| Pfizer INC. | $167.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $165.95 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.83 | 2020-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $89.66 | 2023-2025 | Gvoke Hypopen |
| Abbvie INC. | $87.07 | 2023-2025 | |
| Edwards Lifesciences Corporation | $85.38 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $77.89 | 2020-2021 | |
| Dexcom, INC. | $73.34 | 2023-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73.15 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $71.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.15 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.25 | 2019-2022 | |
| Exact Sciences Corporation | $46.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abiomed | $38.91 | 2024 | Impella |
| Allergan, INC. | $34.77 | 2019-2020 | |
| Dynavax Technologies Corporation | $31.10 | 2023 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $27.46 | 2024 | Voquezna |
| Cepheid | $24.16 | 2024 | Genexpert |
| Actelion Pharmaceuticals US, INC. | $20.33 | 2024 | Uptravi, Opsumit |
| Ekos Corporation | $19.47 | 2019 | |
| Merck Sharp & Dohme LLC | $16.48 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $15.70 | 2025 | Korlym |
| Daiichi Sankyo INC. | $15.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.89 | 2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.85 | 2020 | |
| Shire North American Group INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Manalich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.